Comparative Pharmacology
Head-to-head clinical analysis: BRETHAIRE versus ISOETHARINE HYDROCHLORIDE S F.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BRETHAIRE versus ISOETHARINE HYDROCHLORIDE S F.
BRETHAIRE vs ISOETHARINE HYDROCHLORIDE S/F
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Beta-2 adrenergic receptor agonist; relaxes bronchial smooth muscle by increasing cyclic AMP production via adenylate cyclase activation.
Beta-2 adrenergic receptor agonist; relaxes bronchial smooth muscle by increasing cyclic AMP.
2 inhalations (370 mcg each) by oral inhalation 4 times daily as needed; maximum 12 inhalations per day.
Inhalation: 1-2 inhalations of a 340 mcg/metered dose every 4 hours as needed. Nebulization: 500 mcg (0.5 mL of a 0.1% solution) every 4 hours as needed.
None Documented
None Documented
3.8 hours (terminal elimination half-life; clinical context: dosing interval typically every 4-6 hours)
2-4 hours; clinical context: short half-life supports continuous or repeated dosing for acute bronchospasm.
Renal (25% unchanged, 75% as inactive sulfate conjugates), biliary/fecal (minimal)
Primarily renal excretion of unchanged drug and metabolites; 60-70% excreted in urine as unchanged drug and sulfate conjugates, with less than 10% eliminated in feces via biliary excretion.
Category C
Category C
Beta-2 Adrenergic Agonist
Beta-2 Adrenergic Agonist